Selective COX-2 Inhibitors, NSAIDs, Aspirin, and Myocardial Infarction
- 27 May 2002
- journal article
- editorial
- Published by American Medical Association (AMA) in Archives of Internal Medicine
- Vol. 162 (10), 1091-1092
- https://doi.org/10.1001/archinte.162.10.1091
Abstract
NONSTEROIDAL ANTI-INFLAMMATORY drugs (NSAIDs) are among the most widely used medications in the world.1 NSAIDs inhibit cyclooxygenase-1 (COX-1) and COX-2 isoenzymes. Inhibition of COX-1 isoenzymes inhibits the production of thromboxane and thus inhibits platelet aggregation. In addition, inhibition of COX-1 isoenzymes compromises the gastrointestinal mucosa. As a result, the major limitation of NSAIDs is gastrointestinal toxicity, resulting in upper gastrointestinal events in 2% to 4% of patients per year.1Keywords
This publication has 8 references indexed in Scilit:
- Nonsteroidal Anti-inflammatory Drug Use and Acute Myocardial InfarctionArchives of Internal Medicine, 2002
- Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis.Archives of Internal Medicine, 2002
- Association between naproxen use and protection against acute myocardial infarction.Archives of Internal Medicine, 2002
- Cardiovascular Thrombotic Events in Controlled, Clinical Trials of RofecoxibCirculation, 2001
- Risk of Cardiovascular Events Associated With Selective COX-2 InhibitorsJAMA, 2001
- Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trialsHeart, 2001
- Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2000
- An overview of the 4 randomized trials of aspirin therapy in the primary prevention of vascular disease.Archives of Internal Medicine, 2000